Mood Stabilizers for Bipolar: What They Are and How They Work

The name “mood stabilizer” is a clinical misnomer.

Mood stabilizers do not keep your mood flat. They do not remove emotional experience. They do not cure bipolar disorder. What they do is more specific and, for the people who need them, more valuable: they reduce the frequency and severity of the manic and depressive episodes that define bipolar disorder, and they do so through mechanisms that are genuinely distinct from antidepressants or anxiolytics.

If you have recently been prescribed a mood stabilizer, or if you are trying to understand what your current medication is actually doing in your brain, the name alone does not explain it. The mechanism does.

What This Page Covers

• What mood stabilizers actually do in the bipolar brain
• The three categories and how they differ
• Lithium: mechanism, strengths, and monitoring
• Valproate and lamotrigine: what each does best
• How prescribers decide between them based on your episode pattern
• What to expect in terms of timeline and side effects
• Why stopping when you feel well is the most common cause of relapse
• How continuous monitoring between visits changes outcomes

What Mood Stabilizers Actually Do

About 2.8% of U.S. adults had bipolar disorder in the past year, and an estimated 82.9% of people with bipolar disorder experience serious impairment. Mood stabilizers are the pharmacological foundation of bipolar treatment. Their purpose is not to eliminate mood. It is to prevent the extreme poles from reaching episode-level severity.

Bipolar disorder involves abnormal signaling in the brain circuits that regulate mood, energy, and arousal. During manic episodes, those circuits fire too intensely. During depressive episodes, they become profoundly underactive. Mood stabilizers act on the neurological mechanisms that drive those extremes, bringing the range of amplitude down to a level the person can live within.

The term “mood stabilizer” is a functional label, not a pharmacological class. It covers lithium (an alkali metal ion), anticonvulsants originally developed for epilepsy, and atypical antipsychotics. These medications work through different mechanisms and have different clinical profiles. What they share is a demonstrated ability to reduce episode frequency and severity in bipolar disorder.

High-quality evidence supports using mood stabilizers as a first-line treatment for bipolar disorder, and current clinical guidelines recommend they be continued indefinitely because of the risk of relapse when discontinued.

Lithium: The Gold Standard

Lithium is the oldest and most studied mood stabilizer available. It has been FDA-approved for bipolar disorder since 1970 and remains the most established treatment for classic euphoric mania, with the strongest long-term evidence base across mania, depression prevention, and maintenance.

Its mechanism is still under investigation, but two leading hypotheses are well-supported. The inositol depletion hypothesis proposes that lithium inhibits inositol monophosphatase, which reduces excessive neuronal excitation in overactive brain circuits. Lithium also inhibits GSK-3 beta, a kinase involved in neuronal survival and synaptic plasticity, which may explain its neuroprotective effects beyond symptom control.

Lithium is the only mood stabilizer that has been shown to significantly reduce the risk of suicide in people with bipolar disorder, a clinically important property given that bipolar disorder is associated with elevated lifetime suicide risk. This anti-suicide effect is a meaningful clinical consideration when prescribers choose between options.

Lithium requires about 5 days to reach steady state in the blood and several weeks for full clinical effect. It has a narrow therapeutic window: levels too low produce little clinical benefit, and levels too high can cause toxicity. Blood monitoring at regular intervals is non-negotiable. Kidney function and thyroid function are also tracked over time, as lithium is processed by the kidneys and can affect thyroid hormone levels with long-term use.

Common side effects include fine tremor, increased thirst and urination, and weight gain in some patients. Many of these are dose-dependent and can be managed with timing adjustments or dose modification. Lithium is particularly effective for classic euphoric mania and for patients with a strong family history of the disorder.

Anticonvulsants: Valproate and Lamotrigine

Anticonvulsants were developed for epilepsy but showed mood-stabilizing properties in bipolar disorder through overlapping mechanisms: they reduce hyperactivity in neural circuits, affecting sodium channels, GABA enhancement, and other signaling pathways that regulate neuronal excitability.

Valproate (Depakote)

Valproic acid is often used for acute mania because it can be titrated quickly, making it a practical choice when rapid stabilization is clinically important. It is also effective for mixed episodes and rapid cycling presentations, where lithium shows less benefit.

Valproate’s main side effect concerns include weight gain, sedation, and, critically, significant teratogenic risk. Women of childbearing age prescribed valproate must be counseled about this risk before starting. Regular blood monitoring of drug levels and liver function is required.

Lamotrigine (Lamictal)

Lamotrigine may be the most effective mood stabilizer specifically for depression in bipolar disorder, but it is less helpful for mania. For patients whose bipolar disorder is depression-dominant, lamotrigine is often the first choice or a key component of combination treatment.

Its tolerability profile is notably favorable: lamotrigine is generally weight-neutral, carries no significant metabolic risk, and does not require routine blood monitoring once a therapeutic dose is reached.

The major clinical caution with lamotrigine is its titration. The starting dose must be very low and increased slowly over at least four to six weeks. This approach is essential to minimize the risk of Stevens-Johnson syndrome, a rare but potentially serious skin reaction. Patients should be instructed to report any new rash immediately. Lamotrigine is frequently combined with lithium or an atypical antipsychotic to provide coverage for both depressive and manic phases.

How Prescribers Choose Between Them

Mood stabilizers are not interchangeable. The clinical decision hinges on the pattern of the illness, not just the diagnosis.

Different mood-stabilizing agents have strengths and weaknesses that depend on their indications, side effect profiles, and monitoring requirements. Here is the clinical logic:

For classic euphoric mania: Lithium is the first choice. Its evidence for acute mania and for reducing rehospitalization for mania is the strongest in the class.

For mixed episodes, rapid cycling, or agitated mania: Valproate or an atypical antipsychotic is typically preferred. Lithium shows weaker evidence in these presentations.

For bipolar depression: Lamotrigine is often favored for its antidepressant-dominant profile. Atypical antipsychotics with FDA approval for bipolar depression (quetiapine, lurasidone, cariprazine) are also options.

For maintenance (preventing future episodes): Lithium has the most robust long-term evidence. Lamotrigine is commonly used when depressive episodes predominate. Many patients use combination therapy to address both poles.

Your prescriber will also factor in your medical history, kidney and thyroid function (relevant for lithium), weight concerns, reproductive status (critical for valproate), and any prior medication history that provides clues to response or tolerability.

What to Expect: Timeline and Monitoring

Mood stabilizers are not immediately acting medications. Understanding their timelines prevents premature discontinuation.

Lithium reaches steady state in 5 days but takes weeks to produce full clinical effects. Blood levels are typically checked at 5 to 7 days after any dose change, and then quarterly once stable.

Valproate can reach target levels faster due to dose-loading options used in acute mania, but mood stabilization still takes days to weeks at therapeutic levels.

Lamotrigine has the slowest titration schedule: 6 or more weeks are typically required to reach a therapeutic dose. Patients who stop and restart lamotrigine must often retitrate from the beginning.

Most prescribers advise against making a judgment about whether a mood stabilizer is working until you have been at a therapeutic dose for at least 4 to 6 weeks. Partial response at week 2 is not the same as treatment failure.

Why Stopping When You Feel Well Is the Most Common Cause of Relapse

Feeling stable on a mood stabilizer does not mean bipolar disorder is gone. It often means the medication is working. Stopping medication because symptoms have resolved removes the pharmacological intervention that produced that stability.

The risk of relapse after stopping bipolar medications is not gradual. It can be rapid, within weeks of discontinuation in many patients. And relapse after stopping is frequently more severe than episodes that came before, for reasons that are not fully understood but are well-documented clinically.

Pharmacotherapy for bipolar disorder should be continued indefinitely because of the risk of relapse when treatment is stopped. This is a guideline-level recommendation that reflects decades of outcome data on what happens when bipolar patients discontinue medication.

This is one reason that the monitoring relationship between a patient and their prescriber matters as much as the initial prescription decision. What is the medication actually doing between visits? Is sleep changing in a way that might signal a prodromal manic episode? Is the depressive component increasing in a way the lamotrigine alone cannot address? Daily check-in data changes what a prescriber can see.

About SiggyMD

SiggyMD’s clinical scope covers anxiety and depression, including the mood and anxiety components that frequently accompany bipolar disorder. Bipolar disorder as a primary diagnosis requires a psychiatrist or prescriber with specific expertise in mood disorder management, including the lithium or valproate monitoring that may be involved.

For people managing confirmed bipolar disorder who also have significant co-occurring anxiety and depression, SiggyMD provides the medication oversight and daily monitoring for those conditions between prescribing visits.

“Mood stabilizer selection is one of the more nuanced decisions in outpatient psychiatry,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “The medications have genuinely different profiles. Lithium’s antisuicidal properties matter clinically. Lamotrigine’s tolerability profile matters for adherence. Valproate’s speed in acute mania matters when we need to move fast. The key is matching the medication to the pattern of the illness, not just the diagnosis label. And then the work is making sure the monitoring actually happens between the quarterly appointments.”

The anonymous intake at SiggyMD requires no name, email, or account to begin. A licensed prescriber reviews every treatment plan.

For a complete guide to all bipolar medications, including atypical antipsychotics and the critical antidepressant cautions specific to bipolar disorder, read our bipolar medication guide. For background on how bipolar I and II differ, read our post on bipolar I versus bipolar II.

Start your anonymous intake with SiggyMD to discuss anxiety and depression management as part of your overall care.

What Members Are Saying

DM

D.M., 38

Bipolar I Disorder

“I had been avoiding lithium because of the blood tests. My prescriber finally sat me down and explained why the monitoring exists, what the therapeutic window means, and what the anti-suicide evidence actually shows. None of those things were explained to me when it was first offered. After three months on lithium, the difference in mood stability was significant. The blood tests are a minor inconvenience by comparison.”

RK

R.K., 33

Bipolar II Disorder, Depression-Dominant

“I spent two years failing at various antidepressant combinations before anyone mentioned lamotrigine. When my prescriber explained that bipolar II is often depression-dominant and that lamotrigine was the most evidence-supported option specifically for that, it felt like the first time someone was actually looking at my illness rather than just trying what worked for someone else.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

If you are in crisis or experiencing thoughts of self-harm, call or text 988. If there is immediate danger, call 911.

Sources

1. National Institute of Mental Health. Bipolar Disorder Statistics. NIMH. Accessed June 2026.

2. StatPearls. Mood Stabilizers. NCBI Bookshelf. Updated 2024.

3. Price AL, Marzani-Nissen GR. Bipolar Disorders: A Review. American Family Physician. 2021;103(4):227-239.

4. Centre for Addiction and Mental Health. Mood Stabilizing Medications. CAMH. Accessed June 2026.

5. Cleveland Clinic. Mood Stabilizers: What They Are, How They Work and Side Effects. Cleveland Clinic Health Library. Accessed June 2026.

6. Rapoport SI, et al. Bipolar Disorder and Mechanisms of Action of Mood Stabilizers. Brain Research Reviews. 2009.

7. Merikangas KR, et al. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2007;64(5):543-552.